Cision Wire http://news.cision.com/ Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations. Thu, 23 May 2013 23:31:25 GMT Cision Wire 120 32 http://news.cision.com/ http://news.cision.com/ui/images/CisionLogoSmall.gif BioInvent Presents Positive Data for BI-505 at International Myeloma Congress http://news.cision.com/bioinvent/r/bioinvent-presents-positive-data-for-bi-505-at-international-myeloma-congress,c9395614 cision1293191

]]> Thu, 04 Apr 2013 06:30:00 GMT Positive results from the BI-505 phase I study in multiple myeloma http://news.cision.com/bioinvent/r/positive-results-from-the-bi-505-phase-i-study-in-multiple-myeloma,c9360552 cision1222816

]]> Thu, 24 Jan 2013 07:30:00 GMT BioInvent Interim Report 1 January – 30 September 2012 http://news.cision.com/bioinvent/r/bioinvent-interim-report-1-january---30-september-2012,c9320636 cision1143960

]]> Thu, 18 Oct 2012 07:07:00 GMT BioInvent focuses its business http://news.cision.com/bioinvent/r/bioinvent-focuses-its-business,c9312342 cision1129240 Tue, 02 Oct 2012 06:55:00 GMT BioInvent reorganises http://news.cision.com/bioinvent/r/bioinvent-reorganises,c9278961 cision513284 Fri, 29 Jun 2012 06:30:00 GMT Anti-cancer activity of BI-505 demonstrated in animal model http://news.cision.com/bioinvent/r/anti-cancer-activity-of-bi-505-demonstrated-in-animal-model,c9198476 cision428766 Results presented at American Society of Hematology

]]> Mon, 12 Dec 2011 07:30:00 GMT BI-505 data at American Society of Hematology http://news.cision.com/bioinvent/r/bi-505-data-at-american-society-of-hematology,c9195152 cision425251

]]> Fri, 02 Dec 2011 07:30:00 GMT BioInvent holds Capital Markets Day in Stockholm http://news.cision.com/bioinvent/r/bioinvent-holds-capital-markets-day-in-stockholm,c9183821 cision414547 Detailed review of BioInvent’s programmes, including its lead products, BI-204 (cardiovascular disease) and TB-402 (anti-Factor VIII)

]]> Tue, 08 Nov 2011 07:00:00 GMT BioInvent Interim Report 1 January – 30 June 2011 http://news.cision.com/bioinvent/r/bioinvent-interim-report-1-january---30-june-2011,c9145096 cision368535 Thu, 14 Jul 2011 06:30:00 GMT BioInvent and ThromboGenics Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche http://news.cision.com/bioinvent/r/bioinvent-and-thrombogenics-announce-the-start-of-new-study-of-novel-antibody-anti-cancer-agent-tb-403--anti-plgf--by-partner-roche,c9123005 cision346618 Two new studies now ongoing: phase Ib/II in patients with aggressive brain tumour and phase Ib in primary liver cancer

]]> Mon, 16 May 2011 06:00:43 GMT